Madrigal Pharmaceuticals Insider Trades
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 5 · $35.02M
- Sales
- 76 · $18.01M
- Shares bought / sold
- 91.81K / 35.79K
- Net activity
- Net buying $17.0 million
Madrigal Pharmaceuticals insider activity
Over the last 12 months, Madrigal Pharmaceuticals insiders reported 100 transactions on SEC Form 4: 5 open-market purchases and 76 sales. Insiders bought $35.0 million and sold $18.0 million worth of stock, for net insider buying of $17.0 million. The largest seller was Sibold William John, with $9.1 million in reported sales.
The most recent filing shows Kelley Shannon T (General Counsel) selling 1,077 shares at $400.00 on Nov 6, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put MDGL's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
MDGL insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 6, 2026 | BAKER BROS. ADVISORS LP & Baker Bros. Advisors (GP) LLC & BAKER FELIX & BAKER JULIAN & 667, L.P. & Baker Brothers Life Sciences LPDirector | Buy | 2,000 | $793.22K | Form 4 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP & Baker Bros. Advisors (GP) LLC & BAKER FELIX & BAKER JULIAN & 667, L.P. & Baker Brothers Life Sciences LPDirector | Buy | 13,740 | $5.34M | Form 4 |
| Nov 6, 2026 | BAKER BROS. ADVISORS LP & Baker Bros. Advisors (GP) LLC & BAKER FELIX & BAKER JULIAN & 667, L.P. & Baker Brothers Life Sciences LPDirector | Buy | 60,400 | $23.13M | Form 4 |
| Nov 6, 2026 | Kelley Shannon TGeneral Counsel | Sale | 1,077 | $430.80K | Form 4 |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP & Baker Bros. Advisors (GP) LLC & BAKER FELIX & BAKER JULIAN & 667, L.P. & Baker Brothers Life Sciences LPDirector | Buy | 10,080 | $3.71M | Form 4 |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP & Baker Bros. Advisors (GP) LLC & BAKER FELIX & BAKER JULIAN & 667, L.P. & Baker Brothers Life Sciences LPDirector | Buy | 5,586 | $2.05M | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 120 | $65.57K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 761 | $414.62K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 1,539 | $837.25K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 1,202 | $652.21K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 368 | $199.32K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 687 | $371.38K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 160 | $86.02K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 218 | $116.84K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 106 | $56.61K | Form 4 |
| Sep 11, 2026 | Sibold William JohnPresident and CEO | Sale | 60 | $31.99K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 160 | $86.81K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 362 | $196.08K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 505 | $272.80K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 215 | $115.89K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 520 | $279.91K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 640 | $343.79K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 1,040 | $557.56K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 644 | $344.72K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 396 | $211.54K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 512 | $272.94K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 368 | $195.77K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 522 | $276.78K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 347 | $183.66K | Form 4 |
| Sep 9, 2026 | Sibold William JohnPresident and CEO | Sale | 131 | $69.15K | Form 4 |
| Aug 17, 2026 | Kelley Shannon TGeneral Counsel | Sale | 664 | $341.94K | Form 4 |
| Aug 15, 2026 | REED JOHN CDirector | Award | 647 | — | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 280 | $155.41K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 1 | $550.72 | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 153 | $84.15K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 47 | $25.80K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 680 | $372.43K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 269 | $147.16K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 275 | $150.07K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 545 | $296.87K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 110 | $59.82K | Form 4 |
| Jul 20, 2026 | Sibold William JohnPresident and CEO | Sale | 140 | $75.98K | Form 4 |
| Jul 17, 2026 | Sibold William JohnPresident and CEO | Option exercise | 50,000 | — | Form 4 |
| Jun 17, 2026 | BAKER BROS. ADVISORS LP & 667, L.P. & Baker Bros. Advisors (GP) LLC & Baker Brothers Life Sciences LP & BAKER FELIX & BAKER JULIANDirector | Award | 908 | — | Form 4 |
| Jun 17, 2026 | BAKER BROS. ADVISORS LP & 667, L.P. & Baker Bros. Advisors (GP) LLC & Baker Brothers Life Sciences LP & BAKER FELIX & BAKER JULIANDirector | Award | 908 | — | Form 4 |
| Jun 17, 2026 | Brennan Daniel J.Director | Award | 404 | — | Form 4 |
| Jun 17, 2026 | FOUSE JACQUALYN ADirector | Award | 454 | — | Form 4 |
| Jun 17, 2026 | Levy Richard SDirector | Award | 454 | — | Form 4 |
| Jun 17, 2026 | Taub RebeccaDirector | Award | 454 | — | Form 4 |
| Jun 17, 2026 | Daly James MDirector | Award | 454 | — | Form 4 |
| Jun 1, 2026 | Soergel DavidChief Medical Officer | Sale | 1,042 | $516.56K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 80 | $41.60K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 782 | $405.67K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 1,497 | $774.84K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 723 | $373.69K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 657 | $338.96K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 343 | $176.53K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 40 | $20.52K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 439 | $224.99K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 610 | $311.95K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 151 | $77.06K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 320 | $162.64K | Form 4 |
| May 22, 2026 | Levy Richard SDirector | Sale | 40 | $20.27K | Form 4 |
| May 18, 2026 | Soergel DavidChief Medical Officer | Sale | 844 | $435.42K | Form 4 |
| Mar 6, 2026 | Taub RebeccaDirector | Sale | 491 | $212.08K | Form 4 |
| Mar 6, 2026 | Huntsman CaroleChief Commercial Officer | Sale | 419 | $180.98K | Form 4 |
| Mar 6, 2026 | Kelley Shannon TGeneral Counsel | Sale | 360 | $155.50K | Form 4 |
| Mar 6, 2026 | Sibold William JohnPresident and CEO | Sale | 1,663 | $718.32K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 40 | $17.51K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 80 | $34.94K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 80 | $34.83K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 160 | $69.47K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 116 | $50.18K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 120 | $51.71K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 40 | $17.18K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 160 | $68.64K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 80 | $34.23K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 420 | $179.28K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 40 | $17.00K | Form 4 |
| Mar 6, 2026 | Dier MardiEVP and CFO | Sale | 646 | $279.03K | Form 4 |
| Mar 4, 2026 | Soergel DavidChief Medical Officer | Award | 4,374 | — | Form 4 |
| Mar 4, 2026 | Huntsman CaroleChief Commercial Officer | Award | 3,989 | — | Form 4 |
| Mar 4, 2026 | Kelley Shannon TGeneral Counsel | Award | 4,017 | — | Form 4 |
| Mar 4, 2026 | Sibold William JohnPresident and CEO | Award | 14,995 | — | Form 4 |
| Mar 4, 2026 | Dier MardiEVP and CFO | Award | 5,215 | — | Form 4 |
| Mar 2, 2026 | Dier MardiEVP and CFO | Sale | 1,183 | $505.39K | Form 4 |
| Feb 23, 2026 | Levy Richard SDirector | Option exercise | 2,500 | $18.40K | Form 4 |
| Jan 26, 2026 | Taub RebeccaDirector | Sale | 647 | $318.60K | Form 4 |
| Jan 26, 2026 | Sibold William JohnPresident and CEO | Sale | 1,577 | $776.55K | Form 4 |
| Jan 26, 2026 | Huntsman CaroleChief Commercial Officer | Sale | 570 | $281.92K | Form 4 |
| Jan 26, 2026 | Huntsman CaroleChief Commercial Officer | Sale | 340 | $167.42K | Form 4 |
| Jan 26, 2026 | Levy Richard SDirector | Option exercise | 4,000 | $65.84K | Form 4 |
| Jan 20, 2026 | Taub RebeccaDirector | Sale | 2,238 | $1.10M | Form 4 |
| Jan 20, 2026 | Kelley Shannon TGeneral Counsel | Sale | 429 | $215.10K | Form 4 |
| Jan 20, 2026 | Kelley Shannon TGeneral Counsel | Sale | 263 | $129.07K | Form 4 |
| Jan 15, 2026 | Thakkar RitaChief Accounting Officer | Award | 2,398 | — | Form 4 |
| Jan 9, 2026 | Taub RebeccaDirector | Option exercise | 18,410 | $290.88K | Form 4 |
| Jan 9, 2026 | Taub RebeccaDirector | Sale | 200 | $110.25K | Form 4 |
| Jan 9, 2026 | Taub RebeccaDirector | Sale | 40 | $21.83K | Form 4 |
| Jan 9, 2026 | Taub RebeccaDirector | Option exercise | 240 | $3.79K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4